Previous studies have revealed that CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies [32].In this study, we found a new methods to inhibited the BAFFR-positive cell viability by constructing a TriBAFF directing CAR-T cells and further demonstrated their ability to inhibit BAFFR-positive cells both in vitro and in vivo. Lastly, in the CD19KO B relapse lymphoma cell line model, when CD19-CAR-T cells lost their efficacy, the TriBAFF-CAR-T cells caused the lysis of B cell lines. The gene discussed is CD19; the disease is lymphoma.